Do Not Stop Vyvgart During UTI Treatment with Levofloxacin
Vyvgart (efgartigimod alfa) should be temporarily delayed—not permanently stopped—during active urinary tract infection until the infection resolves, then resumed once clinically appropriate. The FDA label explicitly states to "delay VYVGART administration in patients with an active infection until the infection is resolved" 1. This is a temporary hold, not discontinuation of therapy.
Key Management Algorithm
1. Immediate Action During Active UTI
- Delay the next scheduled Vyvgart infusion until UTI symptoms resolve and treatment is complete 1
- Continue levofloxacin treatment as prescribed for the UTI (typically 5-7 days for uncomplicated UTI) 2
- Monitor for clinical signs of infection resolution
2. When to Resume Vyvgart
- Resume Vyvgart once:
- UTI symptoms have resolved
- Patient has completed appropriate antibiotic course
- No fever or systemic signs of infection present
- Clinical assessment confirms infection clearance
3. Monitoring Considerations
The FDA label notes that Vyvgart increases infection risk, with UTIs occurring in 10% of treated patients versus 5% on placebo 1. Real-world data confirms UTI as the most commonly reported adverse event with efgartigimod 3. However, these infections were predominantly mild to moderate in severity and did not require permanent treatment discontinuation 4.
Rationale for Temporary Delay (Not Permanent Stop)
The distinction is critical: The FDA guidance uses "delay" rather than "discontinue" because:
- Vyvgart causes transient reduction in IgG levels and immune function, which could impair infection clearance if administered during active infection 1
- Once the infection resolves, the benefits of continuing Vyvgart for myasthenia gravis management outweigh infection risks
- In clinical practice, patients successfully resume Vyvgart after infection resolution without increased adverse events 4
Levofloxacin Compatibility
Levofloxacin is appropriate for UTI treatment and does not interact with Vyvgart pharmacologically. The 2024 EAU guidelines support levofloxacin 750 mg daily for 5 days as first-line therapy for uncomplicated pyelonephritis 2. There are no contraindications to using fluoroquinolones in patients who will resume Vyvgart after infection clearance.
Common Pitfall to Avoid
Do not permanently discontinue Vyvgart due to UTI. The infection risk is manageable with appropriate monitoring and temporary treatment delays. Permanent discontinuation would leave the underlying myasthenia gravis untreated, significantly impacting quality of life and potentially mortality. The FDA label specifically addresses this by recommending delay rather than discontinuation, with resumption once infection resolves 1.
Practical Timeline
- Day 1-5/7: Complete levofloxacin course while holding Vyvgart
- Day 7-10: Assess for symptom resolution and infection clearance
- Day 10-14: Resume Vyvgart if clinically appropriate (no fever, symptoms resolved, completed antibiotics)
This approach balances infection management with maintaining effective myasthenia gravis control, prioritizing both immediate infection resolution and long-term disease management.